Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology, Eli Lilly to Evaluate Gastric Cancer Treatment

06/10/2021 | 05:35am EDT

By Chris Wack

ALX Oncology Holdings Inc. said it has entered into a clinical trial collaboration and supply agreement with Eli Lilly & Co. to evaluate the combination of ALX148, a next-generation CD47 blocker, and Cyramza ramucirumab, Lilly's anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer.

Under the terms of the agreement, ALX Oncology will conduct a randomized Phase 2/3 study to evaluate the efficacy of ALX148 in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients whose tumors have progressed following treatment with HER2-targeted therapy and chemotherapy. Lilly will supply ramucirumab for this trial.

Financial details of the collaboration agreement are undisclosed.

ALX Oncology owns worldwide commercial rights to ALX148.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-10-21 0735ET

Stocks mentioned in the article
ChangeLast1st jan.
ALX ONCOLOGY HOLDINGS INC. -1.69% 59.29 Delayed Quote.-31.22%
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
ELI LILLY AND COMPANY -1.65% 218.55 Delayed Quote.29.44%
All news about ALX ONCOLOGY HOLDINGS INC.
06/15ALX ONCOLOGY HOLDINGS INC  : Submission of Matters to a Vote of Security Holders..
AQ
06/14ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 He..
GL
06/10ALX ONCOLOGY  : to Collaborate With Lilly on Combination Therapy for Gastric Can..
MT
06/10ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramu..
GL
06/10ALX Oncology, Eli Lilly to Evaluate Gastric Cancer Treatment
DJ
05/18ALX Oncology Announces Upcoming Virtual Investor Conference Participation
GL
05/18ALX ONCOLOGY  : Q1 Loss Narrows
MT
05/17ALX ONCOLOGY  : Reports First Quarter 2021 Financial Results and Provides Clinic..
PU
05/17ALX ONCOLOGY  : Management's Discussion and Analysis of Financial Condition and ..
AQ
05/17ALX ONCOLOGY HOLDINGS INC  : Results of Operations and Financial Condition, Fina..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -72,2 M - -
Net cash 2021 376 M - -
P/E ratio 2021 -33,0x
Yield 2021 -
Capitalization 2 385 M 2 385 M -
EV / Sales 2021 -
EV / Sales 2022 3 406x
Nbr of Employees 24
Free-Float 61,0%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 97,00 $
Last Close Price 59,29 $
Spread / Highest target 73,7%
Spread / Average Target 63,6%
Spread / Lowest Target 43,4%
EPS Revisions
Managers and Directors
NameTitle
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
ALX ONCOLOGY HOLDINGS INC.-31.22%2 385
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628